Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMCCNASDAQ:MBIONYSE:MTNBNASDAQ:NMTR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMCCIM Cannabis$2.71+44.9%$1.61$1.29▼$4.49$6.05M1.149,380 shs3.15 million shsMBIOMustang Bio$1.28-0.8%$1.25$1.01▼$65.00$5.60M2.27332,052 shs45,455 shsMTNBMatinas Biopharma$0.85+6.3%$0.63$0.47▼$9.60$4.32M1.19195,534 shs740,625 shsNMTR9 Meters Biopharma$0.00$0.07▼$6.56$1.04M1.36315,915 shs114 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMCCIM Cannabis+44.92%+58.57%+83.11%+28.50%-25.65%MBIOMustang Bio-0.78%+7.56%+10.34%-53.28%-86.42%MTNBMatinas Biopharma+6.25%+10.39%+32.61%+46.58%+357.73%NMTR9 Meters Biopharma0.00%0.00%0.00%0.00%+6,463.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMCCIM Cannabis0.8441 of 5 stars0.05.00.00.02.00.00.6MBIOMustang Bio0.8888 of 5 stars0.05.00.00.02.20.00.6MTNBMatinas BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ANMTR9 Meters BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMCCIM Cannabis 0.00N/AN/AN/AMBIOMustang Bio 0.00N/AN/AN/AMTNBMatinas Biopharma 2.00HoldN/AN/ANMTR9 Meters Biopharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMCCIM Cannabis$54.47M0.11N/AN/A$4.55 per share0.60MBIOMustang BioN/AN/AN/AN/A$0.67 per shareN/AMTNBMatinas Biopharma$1.10M3.93N/AN/A$4.43 per share0.19NMTR9 Meters BiopharmaN/AN/AN/AN/A$0.19 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMCCIM Cannabis-$7.04M-$0.64N/AN/AN/A-25.55%-129.86%-23.63%8/12/2025 (Estimated)MBIOMustang Bio-$51.60M-$78.00N/AN/AN/AN/AN/A-172.89%8/12/2025 (Estimated)MTNBMatinas Biopharma-$22.94M-$3.86N/A∞N/AN/A-123.06%-94.28%N/ANMTR9 Meters Biopharma-$43.77M-$3.46N/AN/AN/AN/A-584.97%-159.45%N/ALatest NMTR, MTNB, IMCC, and MBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025IMCCIM Cannabis-$0.2540$0.06+$0.3140$0.06$11.45 million$8.69 million5/14/2025Q1 2025MBIOMustang BioN/A-$0.05N/A-$0.05N/AN/A3/31/2025Q4 2024IMCCIM Cannabis-$0.39-$0.23+$0.16-$0.23$14.48 million$9.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMCCIM CannabisN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/AN/AMTNBMatinas BiopharmaN/AN/AN/AN/AN/ANMTR9 Meters BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMCCIM Cannabis0.100.700.59MBIOMustang BioN/A0.400.40MTNBMatinas BiopharmaN/A5.535.53NMTR9 Meters BiopharmaN/A0.590.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMCCIM Cannabis7.68%MBIOMustang Bio9.95%MTNBMatinas Biopharma11.77%NMTR9 Meters Biopharma22.34%Insider OwnershipCompanyInsider OwnershipIMCCIM Cannabis5.91%MBIOMustang Bio0.21%MTNBMatinas Biopharma4.60%NMTR9 Meters Biopharma2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMCCIM Cannabis3402.23 million2.10 millionNot OptionableMBIOMustang Bio1004.38 million952,000Not OptionableMTNBMatinas Biopharma305.09 million4.60 millionN/ANMTR9 Meters Biopharma2014.34 million13.99 millionNo DataNMTR, MTNB, IMCC, and MBIO HeadlinesRecent News About These CompaniesWhat is a prepayment meter?August 24, 2024 | uswitch.comAfter coeliac fail, 9 Meters plots phase 3 in short bowel syndromeJuly 29, 2024 | pharmaphorum.comEnergy firms likely to miss smart meter deadline, warns Which?December 14, 2023 | bbc.comDeal reached to sell some assets of bankrupt Raleigh firmNovember 8, 2023 | bizjournals.com9 Meters Biopharma, Inc. (NMTRQ)November 7, 2023 | finance.yahoo.comTRACK AND FIELD/ Yamagata sets Japan record in 100-meter sprint with 9.95 secondsOctober 28, 2023 | asahi.com9 Meters Biopharma Inc (NMTRQ)October 17, 2023 | investing.comVintage Meters Reborn As Steam Punk ClockOctober 10, 2023 | hackaday.com9 Meters Biopharma (OTC: NMTR.Q)August 16, 2023 | fool.comInsider Sale Alert: 9 Meters Biopharma Inc. [NMTR] – Is it Time to sell?July 25, 2023 | knoxdaily.com9 Meters Biopharma Inc. [NASDAQ: NMTR] Sees Decrease in Stock ValueJuly 21, 2023 | knoxdaily.comRaleigh firm joins worrying trend of bankruptcies for drugmakersJuly 18, 2023 | bizjournals.comDrug developer 9 Meters Biopharma files for bankruptcy protectionJuly 18, 2023 | reuters.comWhy Are 9 Meters Biopharma Shares Nosediving Today?July 18, 2023 | finance.yahoo.comExamining the Potential Price Growth of 9 Meters Biopharma Inc. (NMTR)July 18, 2023 | knoxdaily.comTemperato resigns as CEO of Raleigh drugmakerMay 30, 2023 | bizjournals.com9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel SyndromeMay 30, 2023 | finance.yahoo.com9 Meters Biopharma (NASDAQ: NMTR)May 28, 2023 | fool.comNMTR - 9 Meters Biopharma, Inc.May 25, 2023 | uk.finance.yahoo.comCitigroup Maintains 9 Meters Biopharma (NMTR) Neutral RecommendationMay 19, 2023 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNMTR, MTNB, IMCC, and MBIO Company DescriptionsIM Cannabis NASDAQ:IMCC$2.71 +0.84 (+44.92%) Closing price 05/28/2025 03:59 PM EasternExtended Trading$2.71 0.00 (0.00%) As of 05:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.Mustang Bio NASDAQ:MBIO$1.28 -0.01 (-0.78%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$1.27 -0.01 (-0.39%) As of 06:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.Matinas Biopharma NYSE:MTNB$0.85 +0.05 (+6.25%) Closing price 05/28/2025 03:59 PM EasternExtended Trading$0.87 +0.02 (+2.35%) As of 06:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.9 Meters Biopharma NASDAQ:NMTR9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
